Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Table 5 Univariate and multivariate analyses of the prognostic factors for overall survival

Factors	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
AFP (≤ 1210 vs > 1210), ng/mL	0.59 (0.36-0.95)	0.031	0.42 (0.25-0.72)	0.002
Age (≥ 60 vs < 60), years	0.70 (0.43-1.12)	0.139	-	-
Alcohol (yes vs no)	1.02 (0.64-1.63)	0.932	-	-
ALT (≤ 40 vs > 40), U/L	1.21 (0.77-1.92)	0.409	-	-
BCLC stage (C vs B)	0.59 (0.37-0.94)	0.028	0.43 (0.26-0.70)	0.001
BMI (normal vs overweight/obesity)	0.39 (0.21-0.70)	0.002	0.22 (0.11-0.45)	< 0.001
Child-Pugh score (B vs C)	0.77 (0.48-1.22)	0.266	-	-
Diabetes (yes vs no)	0.92 (0.52-1.60)	0.755	-	-
Cirrhosis (yes vs no)	1.15 (0.72-1.84)	0.562	-	-
ECOG (2 vs 0-1)	0.66 (0.40-1.07)	0.090	-	-
HBe (positive vs negative)	1.09 (0.67-1.78)	0.717	-	-
HBV-DNA (HBV ≤ 2000 vs HBV > 2000), IU/mL	0.67 (0.42-1.07)	0.091	-	-
Hypertensive (yes vs no)	1.20 (0.71-2.05)	0.494	-	-
PVTT (yes vs no)	2.36 (1.35-4.12)	0.003	2.23 (1.26-3.93)	0.006
Metastasis (yes vs no)	0.79 (0.50-1.26)	0.328	-	-
Sex (male vs female)	1.11 (0.70-1.77)	0.658	-	-
Smoking (yes vs no)	1.33 (0.81-2.19)	0.266	-	-
Total bilirubin (≤ 34 vs > 34), μmol/L	1.26 (0.78-2.02)	0.348	-	-
Interventional (yes vs no)	0.75 (0.47-1.19)	0.224	-	-

HR: Hazard ratio; CI: Confidence interval; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; BMI: Body mass index; BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; HBV: Hepatitis B virus; PVTT: Portal vein tumor thrombosis.